LongBio pharma is a China-based biotech aiming for worldwide development of innovative therapeutic biologics. In the past decades, the innovation and entrepreneur team established a track record by one blockbuster antibody in a continuously growing market, several long acting therapeutic proteins and antibodies in early or late clinical stages. Based on our unique research and development platforms such as long acting fusion proteins, high profile antibodies, leading mammalian cell culture process, and other proprietary technologies, LongBio is developing several drug candidates for blood diseases, allergy disease, cancers and other rare diseases. Equipped with the most advanced instruments and facilities, the state of art technology and modern infrastructure, LongBio is fully committed to innovation for global patients to meet the unmet medical needs. The most advanced project will enter into global clinical development soon.